Aligos Therapeutics, Inc.
ALGS
$7.22
-$0.43-5.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -23.04M | -19.88M | -31.54M | -15.86M | 43.09M |
| Total Depreciation and Amortization | 346.00K | 257.00K | 220.00K | 259.00K | 194.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.99M | 293.00K | 5.44M | -830.00K | -60.36M |
| Change in Net Operating Assets | 1.56M | -2.41M | 1.53M | 930.00K | -3.84M |
| Cash from Operations | -23.13M | -21.75M | -24.35M | -15.50M | -20.91M |
| Capital Expenditure | -69.00K | -92.00K | -193.00K | -109.00K | -43.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.00M | -1.93M | 47.88M | -39.31M | -44.02M |
| Cash from Investing | 34.93M | -2.02M | 47.68M | -39.42M | -44.07M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -62.00K | -3.00K | -10.00K | -1.00K | -- |
| Issuance of Common Stock | -- | 126.00K | -- | -- | 101.74M |
| Repurchase of Common Stock | -- | -- | -43.00K | -176.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -62.00K | 123.00K | -53.00K | -177.00K | 101.74M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.74M | -23.64M | 23.29M | -55.10M | 36.77M |